Overview
Compounds in this area appear in the tissue-repair and recovery literature, often studied for angiogenesis, cytoprotection, and cell-migration signaling. The evidence base is predominantly preclinical, so this guide labels the study type for every cited claim and never reads animal or in-vitro data as human efficacy.
A pre-formulated research blend combining GHK-Cu, BPC-157, TB-500, and KPV, studied together in recovery-research contexts.
Evidence at a glance: No efficacy evidence cited
No published efficacy evidence is cited for this compound. We state that plainly rather than pad the page.
Molecular identity
- Molecular formula
- Multi-component blend
- Molecular weight
- Mixed
- CAS number
- Blend (see components)
- Appearance
- White lyophilized powder (blend)
- Purity (HPLC)
- 98.5%
Researched mechanism
Combines the individual mechanisms of its four components; no combined-formulation clinical data exists.
Described as a mechanism characterized in the literature, not an effect you should expect from use.
Evidence
Honest note on evidence: This is a blend. There is no published research on the combination as a single formulation; see each component's page for its individual (mostly preclinical) evidence.
How it compares
| Versus | Attribute | Note |
|---|---|---|
| GLOW | Composition | GLOW is a lighter GHK-Cu/BPC/TB skin-focused blend; KLOW adds KPV. |
Reconstitution
Concentration math only: adding bacteriostatic water to the vial gives the resulting mg/mL shown below. This is not usage guidance.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 80 mg | 3 mL | 26.67 mg/mL |
Storage & stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unopened) | -20°C | 24 months |
| Reconstituted | 2–8°C | up to 3 weeks |
Common questions
Is there a COA for the blend?+
Yes. The COA reflects the combined product. Component-level evidence lives on each component's page.
